1Panov GP, Pacheva LH, Bojinov PS. Effectiveness of lamotrigine for attentlon-deficit hyperactivity disorder in patients with epilepsy[J].Epilepsia, 2005, 46 (suppl 6): 179-182.
2Lhatoo SD, Wong ICK, Sander JW. Prognostic factor affecting long-term retention of topiramate in patients with chronic epilepsy[J]. Epilepsia, 2000,41:338-341.
3Engel J. ILAE commission report. A proposed diagnostic scheme for people with epileptic seizures and with epilepsy: report of ILAE Task Force on classification and terminology[J]. Epilepsia, 2001,42(6) :769-803.
4Ahmad S, Fowler LJ, Whitton PS. Effects of combined lamotrigine and valproate on basal and stimulated extracellular amino acids and monoamines in the hippoeampus of freely moving rats[J]. Naunyn Schmiedebergs Arch Pharmacol, 2005, 371 : 1-8.
5Aldenkamp AP. Cognitive and behavioural assessment in clinical trials: when should they he done? [J] . Epilepsy Res, 2001, 45:155-159.
6Marson AG, Hutton JL, Leach JP, et al. levetiracetam, oxcarbamazepine, remaeemide and zonisamide for drug resistant localization-related epilepsy:a systematic review[J]. Epilepsy Res, 2001, 46:259-270.
2Kang HC,Eun BL,Wu Lee C,et al.The effects on cognitivefunction and behavioral problems of topiramate compared to carbam-azepine as monotherapy for childrenwith benign rolandic epilepsy[J].Epilepsia,2007,48(12):1716-1723.
3Chen J,Quan QY,Yang F,et al.Effects of lamotrigine and topiramate on hippo campal neurogenesis in experimental temporallobeepilepsy[J].Brain Res,2010,8(8):270-282.
